Loading organizations...
§ Venture Capital · Beijing, China
Private equity investment platform providing growth-stage capital and strategic services for information technology and medical health.
Junxin Capital is a private equity investment platform providing growth-stage capital primarily to companies in the information technology and medical health sectors. The firm operates as a fully market-oriented entity of the Junyao Group-Aijian Group, leveraging resources from its shareholders and institutional investors. It targets high-quality enterprises, with a particular focus on lead companies within the Yangtze River Delta, Beijing, and Guangzhou-Shenzhen regions. Beyond capital deployment, Junxin Capital offers strategic services including corporate governance, strategic planning, business development, listing, and mergers and acquisitions. Recognizable shareholders of the platform include Junyao Group and Aijian Group. Junxin Capital was established in 2017; specific founder names are not publicly available. Its business model centers on private equity firm raising and deploying growth capital into portfolio companies, leverages resources from shareholders and institutional investors.
Junxin Capital has 1 tracked investment across 1 company. The latest tracked deal is $100.0M Series C in Zhenge Biotech in January 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2022 | Zhenge Biotech | $100.0M Series C | Kevin XU, Xiao Tian LOI | Qiming Venture Partners, IDG Capital, Lyfe Capital, Amit Kakar MD |